Neurocrine Biosciences Reports 44% Surge in Q1 Revenue, Pursues Acquisition of Rare Disease Company Worth 4 Trillion Won

Neurocrine Biosciences (NASDAQ: NBIX) reported first-quarter 2026 net product sales of $811 million (approximately KRW 1.1 trillion), a 44% increase year-over-year, and total revenues of $814.5 million (about KRW 1.14 trillion).

The primary drivers of growth were movement-disorder treatment INGREZZA and congenital adrenal hyperplasia therapy CRENESSITY. The company reaffirmed its 2026 annual sales guidance for INGREZZA of $2.7 billion to $2.8 billion (roughly KRW 3.8 trillion to KRW 4.0 trillion).

To secure VYKAT XR, a hyperphagia treatment for Prader-Willi syndrome, Neurocrine agreed to acquire rare-disease specialist Soleno Therapeutics at $53 per share, for a total of $2.9 billion (around KRW 4 trillion). The company has also initiated Phase 1/2 clinical trials for its schizophrenia candidate NBI-1117570 and its obesity asset NBIP-’2118.

Recently, Neurocrine launched the first-in-human Phase 1 trial of NBIP-’2118 targeting obesity and presented two-year long-term data in pediatric and adult CRENESSITY patients, accelerating its endocrine portfolio expansion.

Additionally, the U.S. FDA granted orphan-drug designation to its Friedreich’s ataxia candidate, further broadening the company’s rare neurologic-disease pipeline.

Listed on Nasdaq, Neurocrine specializes in neuropsychiatric, neurologic and endocrine disorders. In addition to INGREZZA and CRENESSITY, it commercializes therapies for endometriosis, uterine fibroids and rare endocrine diseases, positioning itself at the heart of intense global competition in rare-disease and obesity M&A and drug development.